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Abstract
Background: Bupropion is approved for the treatment of mood disorders and as an adjuvant
medication for smoking cessation. Bupropion is generally well tolerated and considered safe. Two
randomized controlled trials of bupropion therapy for smoking cessation did not report any hepatic
adverse events. However, there are three reports of severe but non-fatal bupropion hepatotoxicity
published in the literature.
Case Presentation: We present the case of a 55-year old man who presented with jaundice and
severe hepatic injury approximately 6 months after starting bupropion for smoking cessation.
Laboratory evaluation demonstrated a mixed picture of hepatocellular injury and cholestasis. Liver
biopsy demonstrated findings consistent with severe hepatotoxic injury due to drug induced liver
injury. Laboratory testing was also notable for positive autoimmune markers. The patient initially
had clinical improvement with steroid therapy but eventually died of infectious complications.
Conclusion: This report represents the first fatal report of bupropion related hepatotoxicity and
the second case of bupropion related liver injury demonstrating autoimmune features. The
common use of this medication for multiple indications makes it important for physicians to
consider this medication as an etiologic agent in patients with otherwise unexplained hepatocellular
jaundice.
Background
Bupropion (Wellbutrin® or Zyban®, GlaxoSmithKline,
Greenville, NC) is approved for the treatment of mood
disorders and as an adjuvant medication for smoking ces-
sation. Bupropion is a weak inhibitor of the neuronal
uptake of norepinephrine, serotonin, and dopamine but
is chemically unrelated to other known antidepressant
drugs including tricyclic and tetracyclic agents as well as
selective serotonin re-uptake inhibitors. The mechanism
by which bupropion enhances the ability of patients to
abstain from smoking is unknown but may involve cen-
tral noradrenergic and/or dopaminergic pathways.
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Each year, nearly 25% of individuals prescribed smoking
cessation aids are started on bupropion SR and there are
an estimated 8.7 million prescriptions of bupropion dis-
pensed each year in the United States. Two randomized
controlled trials of bupropion therapy for smoking cessa-
tion of seven and nine weeks duration did not report any
hepatic adverse events [1]. However, there are three
reports of severe but non-fatal bupropion hepatotoxicity
published in the literature [2-4]. The aim of this paper is
to report the first fatal case of bupropion hepatotoxicity
which presented in an unusual manner, with autoim-
mune features, in a middle aged male who was trying to
stop smoking.
Case presentation
A 55-year-old Caucasian male presented in February 2005
with new onset hematuria, easy bruising, and jaundice.
He also reported fevers, nausea with vomiting and fatigue
in the week prior to presentation without any associated
abdominal pain or pruritus. At presentation, he was afe-
brile and there was no skin rash, hepatosplenomegaly,
asterixis, or stigmata of chronic liver disease but he was
deeply jaundiced with scleral icterus and multiple ecchy-
moses. Initial laboratory tests included a white blood cell
count of 13.7 (4.0–10.0 K/UL) with a left shift, hemo-
globin 15.5 (13.5–17.5 GM/DL), platelets 200 (140–450
K/UL), AST 1466 (20–57 IU/L), ALT 1459 (21–72 IU/L),
total bilirubin 5.3 (0.0–1.5 mg/dl), direct bilirubin 4.9
(0.0–0.8 mg/dl), alkaline phosphatase 219 (30–136 IU/
L), INR 13, and prothrombin time 145.8 (10.0–13.5 sec).
Serum liver biochemistries were normal 4 months prior
(AST 32 IU/L, ALT 40 IU/L, Total Bilirubin 0.5 mg/dl). An
abdominopelvic CT scan without contrast was unremark-
able.
The patient had a history of mild depression, hyperten-
sion, and hyperlipidemia. He denied using intravenous
drugs or recent travel or sick contacts. He had discontin-
ued alcohol in 2002 but smoked a half-pack of cigarettes
for the past 8 years. He was receiving warfarin for a pros-
thetic mitral valve since 2002 and had a previously stable
and therapeutic INR. His other medications for the past 3
years included metoprolol XL, atorvastatin, and aspirin.
Paroxetine had been started shortly after surgery and dis-
continued in May 2004 but restarted in October 2004 for
recurrent depressive symptoms. Bupropion 150 mg bid
was started for smoking cessation in July 2004 and was
continued up until hospitalization (6 months of treat-
ment). The patient reported never having received bupro-
pion or other anti-depressants beyond the paroxetine
previously. He also denied ingesting over the counter
products such as acetaminophen or herbals. He had aller-
gies to penicillin and sulfa drugs that caused hives.
After receiving several units of fresh frozen plasma, he was
temporarily placed on intravenous heparin. Diagnostic
studies included a serum iron of 193 ug/dl, transferrin sat-
uration of 55%, and ferritin of 974 mg/dl but subsequent
hemochromatosis genotyping was negative. Serum ceru-
loplasmin was normal at 28 mg/dl. Serological studies for
acute hepatitis A IgM, hepatitis B surface antigen and anti-
HB core antibody, and hepatitis C RNA by PCR as well as
CMV and EBV serologies were negative. However, an anti-
nuclear antibody (ANA titer = 1:160; speckled pattern)
and anti-smooth muscle antibody (ASMA titer = 1:40)
were positive. A surface echocardiogram revealed an ejec-
tion fraction of 75–80%. Despite withdrawal of all outpa-
tient medications, his serum aminotransferases and
bilirubin continued to rise (Figure 1). A transjugular liver
biopsy revealed severe interface hepatitis with intense
peri-portal inflammatory infiltrate consisting of a mixture
of lymphocytes, eosinophils, and a few scattered plasma
cells (Figure 2). A reticulin stain showed hepatic collapse
with crowding of the reticulin meshwork and loss of hepa-
tocytes. A trichrome stain did not reveal established fibro-
sis. A pathological diagnosis of a severe hepatotoxic injury
due to a drug with autoimmune-like features was made.
Serial serum alanine aminotransferase and total bilirubin lev-elsFigure 1
Serial serum alanine aminotransferase and total bilirubin lev-
els. The patient's serum ALT and total bilirubin initially 
improved with a short course of oral corticosteroids. How-
ever, 3 weeks after discontinuing the prednisone, his serum 
ALT markedly increased and he was rehospitalized. Despite 
high doses of corticosteroids, he developed progressive 
mental status changes and died 105 days after initial presen-
tation with sepsis and liver failure.Page 2 of 5
(page number not for citation purposes)
Journal of Medical Case Reports 2007, 1:88 http://www.jmedicalcasereports.com/content/1/1/88Because of the persistent severe biochemical injury, the
patient was started on prednisone 60 mg/day. Over the
next 13 days, the serum ALT levels trended down (Figure
1). His total bilirubin peaked at 22.7 mg/dl and his ALT
reached a second peak at 1357 IU/L before trending down
over the next four weeks. The patient's INR remained dif-
ficult to manage even with lower doses of coumadin,
ranging between 1.6 and 3.7. However, the INR values
became more stable at approximately 20 days after insti-
tution of prednisone therapy. Upon referral to the Univer-
sity of Michigan, a repeat ANA was higher at 1:1280 and
serum IgG, IgM, and IgA levels were 1510 mg/dl, 125 mg/
dl, and 367 mg/dl, respectively. At this point, the patient
felt much improved and his prednisone was tapered off
over 6 weeks. The patient was discharged on prednisone,
metoprolol and coumadin. Three weeks later his transam-
inases began to rise but his bilirubin remained
unchanged. Repeat testing two weeks later showed
marked elevation of his total bilirubin to 23.7 mg/dl and
ALT to 961 IU/L and he was readmitted to the hospital for
a possible repeat liver biopsy. A decision was made to
forego the liver biopsy and restart the patient on pred-
nisone 60 mg per day and he was discharged home. How-
ever, two days later his total bilirubin increased to 37.4
mg/dl and his ALT was 1158 IU/L. He was then admitted
to the hospital for liver transplantation evaluation with
new onset mental status changes. The patient was started
on broad-spectrum antibiotics. The patient's condition
quickly deteriorated with the onset of encephalopathy
and coagulopathy. On hospital day 13, he developed res-
piratory failure and was transferred to the ICU but he died
of multiorgan failure the next day. An autopsy revealed
coronary artery disease but otherwise intact myocardium.
His liver was shrunken and weighed 1320 grams and there
was evidence of extensive necrosis, predominantly central
zone, with cholestasis. He also had bilateral aspergillus
pneumonia, which had previously not been recognized.
There was no evidence of other solid organ infection. His
death was attributed to sepsis resulting from acute liver
failure.
Conclusion
Bupropion is an effective medication to assist in smoking
cessation [1]. Although preclinical studies demonstrated
mild, reversible hepatotoxicity in laboratory animals
receiving large doses of bupropion for prolonged periods
of time [5], initial clinical trials demonstrated an inci-
dence of < 1% of abnormal liver biochemistries. In addi-
tion, despite its availability for over 15 years in clinical
practice, only 3 cases of bupropion hepatotoxicity have
been published in the medical literature [2-4]. In each of
these reports, the afflicted subjects had an acute hepato-
cellular injury pattern developing within 6 months of
drug initiation (Table 1). The current patient began
bupropion SR for smoking cessation with previously nor-
mal liver biochemistries. All of his other medications were
longstanding except paroxetine which was restarted in
October 2004. Although paroxetine can lead to acute
hepatocellular liver injury, the patient had previously
received this medication for over 2 years without adverse
events. While previous use of the paroxetine could be the-
orized to have sensitized the patient to retreatment, we
feel that the patient's overall clinical course and previ-
ously reported case of bupropion-induced liver injury pre-
senting with autoimmune features support our
conclusion that bupropion was the most likely inciting
agent. Similarly, although warfarin can rarely cause chole-
static liver injury, the continuous use of warfarin for over
Liver biopsyFigure 2
Liver biopsy. (Top) H&E stain showing severe necrosis in the 
peri-portal region with a mixed population of lymphocytes, 
eosinophils, and small clusters of plasma cells. (Bottom) Reti-
culin stain showing crowded reticulin meshwork and drop 
out of hepatocytes consistent with hepatic collapse. (Magnifi-
cation of top and bottom, ×400 and ×200).Page 3 of 5
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hepatocellular liver injury pattern and lack of hypersensi-
tivity features.
Six months after starting bupropion he presented with
markedly elevated serum aminotransferase and bilirubin
levels (Figure 1). His time course is consistent with an idi-
osyncratic drug reaction, which typically occurs within 1
year of starting a new medication [6]. The biochemical
profile was a severe acute hepatocellular injury with
autoimmune features. Other prescription medications
such as minocycline, pemoline, and nitrofurantoin have
also been associated with an acute hepatitis with autoim-
mune features [7]. One prior case of bupropion induced
liver injury presented similarly with marked elevation of
serum aminotransferase levels and a positive ANA [4].
Our patient was enrolled in the Drug Induced Liver Injury
Network (DILIN) prospective protocol wherein all other
known competing causes of liver injury were excluded [6].
Using the widely cited Roussel Uclaf Causality Assessment
method (i.e. RUCAM), this case scored 8 which is catego-
rized as a "highly probable" case of DILI. This case was
also scored as "probable" on a drug-induced hepatitis val-
idation scale [8]. On the other hand, this case was also
scored as "probable" autoimmune hepatitis on the Inter-
national autoimmune hepatitis consensus scale due to the
presence of autoantibodies, liver biopsy findings, and ini-
tial response to prednisone [9]. Overall, we feel that this
patient presumably developed fulminant hepatitis with
autoimmune features due to bupropion in light of the
temporal course, exclusion of competing etiologies, and
compatible liver histology.
"Hy's rule", named after Hyman Zimmerman, has been
used to aid in determining the prognosis in cases of DILI.
With "Hy's rule" patients with acute hepatocellular DILI
and a total bilirubin greater than 2 times the upper limit
of normal are anticipated to have a ~10% mortality. This
finding was recently validated in a large retrospective
series from Sweden [10]. In subjects with severe drug-
induced hepatitis that go on to develop encephalopathy
and coagulopathy, the likelihood of recovery is even
poorer with only a 25% rate of spontaneous survival [11].
Unfortunately, this patient developed a progressive and
fatal course despite the cessation of the suspect medica-
tion and use of corticosteroids highlighting the utility of
"Hy's rule" in identifying DILI patients with a potentially
poor prognosis.
The primary management of DILI includes the identifica-
tion and immediate withdrawal of the inciting agent.
There is anecdotal evidence that ursodeoxycholic acid
may hasten the resolution of liver biochemical abnormal-
ities but randomized, prospective studies are lacking
[12,13]. There are also unproven recommendations of
using corticosteroids in immune mediated DILI [4,6].
However, previous controlled trials demonstrated no sur-
vival benefit with corticosteroid use in fulminant hepati-
tis. There is also evidence that steroids may increase the
risk of bacterial and fungal infections. In the present case,
the patient initially showed significant improvement after
the bupropion SR was stopped and corticosteroid treat-
ment was started. The steroids most likely acted by atten-
uating the ongoing drug induced autoimmune liver
damage. Unfortunately, he experienced a severe biochem-
ical relapse after the corticosteroids were tapered which
did not respond to retreatment. After progressing to fulmi-
nant liver failure, he died with disseminated aspergillosis
which was likely related, in part, to the immunosuppres-
sive effect of the corticosteroids. However, fungal infec-
tions may develop in 20 to 30% of patients with acute
liver failure even in the absence of corticosteroids due to
impaired host immune surveillance.
In summary, bupropion is a safe and effective treatment
for millions of patients with depression and others seek-
ing to stop smoking. However, as with many other drugs
used in clinical practice, there are rare instances of idio-
syncratic hepatotoxicity associated with bupropion use.
The previously published cases of bupropion hepatotoxic-
ity have all occurred within the first 6 months of medica-
tion use and presented with a hepatocellular injury
pattern (Table 1). Based upon the clinical presentation,
histological findings and time course, it is our opinion
that this case is the first reported instance of fatal bupro-
pion hepatotoxicity. Although bupropion hepatotoxicity
is rare and unpredictable, practicing physicians should be
aware of this adverse effect when evaluating patients with
Table 1: Published reports of bupropion hepatotoxicity
Author (yr) Dose Duration of use 
(Days)
Peak ALT (IU/L) Peak bilirubin (mg/
dl)
Outcome
Oslin ('93) 300 mg QD × 21 days, 
then 400 mg QD
54 5.4 × ULN Not reported Resolution
Hu ('00) 200 mg QD 42 6660 3.8 Resolution
D. Alvaro ('01) 150 mg BID 20 49 × ULN 38 Resolution
Humayun ('07) 150 mg BID 180 20 × ULN 37 Death
ULN = Upper limit of normalPage 4 of 5
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unexplained jaundice or liver biochemistry abnormalities.
In addition, bupropion should be considered as a precip-
itating cause of an acute autoimmune-like hepatitis as has
been reported with other prescription medications.
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